Meta-analysis of the role of C-reactive protein in predicting severity of acute pancreatitis

Pancreatology ◽  
2013 ◽  
Vol 13 (2) ◽  
pp. e39-e40
Author(s):  
T. Jin ◽  
K. Altaf ◽  
J.J. Xiong ◽  
M.A. Javed ◽  
W. Huang ◽  
...  
Keyword(s):  
Acute Pancreatitis ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions

2020 ◽  
Vol 9 (7) ◽  
pp. 2244 ◽  
Author(s):  
Matteo Nicola Dario Di Minno ◽  
Ilenia Calcaterra ◽  
Roberta Lupoli ◽  
Antonio Storino ◽  
Giorgio Alfredo Spedicato ◽  
...  
Keyword(s):  
Regression Models ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Long Term Outcomes ◽  
Chronic Disability ◽  
Reactive Protein ◽  
The Difference ◽  
D Dimer

Background: Complications of coronavirus disease 2019 (COVID-19) include coagulopathy. We performed a meta-analysis on the association of COVID-19 severity with changes in hemostatic parameters. Methods: Data on prothrombin time (PT), activated partial thromboplastin time (aPTT), D-Dimer, platelets (PLT), or fibrinogen in severe versus mild COVID-19 patients, and/or in non-survivors to COVID-19 versus survivors were systematically searched. The standardized mean difference (SMD) was calculated. Results: Sixty studies comparing 5487 subjects with severe and 9670 subjects with mild COVID-19 documented higher PT (SMD: 0.41; 95%CI: 0.21, 0.60), D-Dimer (SMD: 0.67; 95%CI: 0.52, 0.82), and fibrinogen values (SMD: 1.84; 95%CI: 1.21, 2.47), with lower PLT count (SMD: −0.74; 95%CI: −1.01, −0.47) among severe patients. Twenty-five studies on 1511 COVID-19 non-survivors and 6287 survivors showed higher PT (SMD: 0.67; 95%CI: 0.39, 0.96) and D-Dimer values (SMD: 3.88; 95%CI: 2.70, 5.07), with lower PLT count (SMD: −0.60, 95%CI: −0.82, −0.38) among non-survivors. Regression models showed that C-reactive protein values were directly correlated with the difference in PT and fibrinogen. Conclusions: Significant hemostatic changes are associated with COVID-19 severity. Considering the risk of fatal complications with residual chronic disability and poor long-term outcomes, further studies should investigate the prognostic role of hemostatic parameters in COVID-19 patients.

scholarly journals Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenhua Liu ◽  
Hongtai Shi ◽  
Longyun Chen
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Pre Treatment

Abstract Background In recent years, the role of pre-treatment C-reactive protein/albumin ratio (CAR) in prognosis of esophageal cancer (EC) has been investigated by several studies. This meta-analysis aimed to provide a more accurate and objective assessment of the prognostic value of pre-treatment CAR in EC. Methods Studies assessing the role of pre-treatment CAR in prognosis of EC were searched from PubMed, Embase and the Cochrane Library (last update by April 16, 2019). The hazard ratios (HRs) of CAR and the corresponding 95% CIs for overall survival (OS) or cancer-specific survival (CSS) in EC were extracted for pooled analysis. Results A total of eight observational studies including 2255 patients were collected. The pooled analysis showed that high CAR was related to worse OS in EC (pooled HR = 1.81; 95% CI = 1.40–2.35; P < 0.001). Subgroup analyses showed that the negative correlation between the CAR and OS was consistently demonstrated in subgroups stratified by country, pathological type, and cut-off value (P < 0.05). However, there was no relation between CAR and OS in subgroup of patients receiving neoadjuvant chemotherapy at a proportion of 100% (HR = 1.15, 95% CI = 0.56–2.69; P = 0.715). In addition, high CAR was also related to worse CSS in EC (pooled HR = 2.61; 95% CI = 1.67–4.06; P < 0.001). Conclusions High pre-treatment CAR was an adverse prognostic factor for EC patients. More large-sample clinical trials are still needed to verify the prognostic value of pre-treatment CAR in EC.

scholarly journals Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis

2014 ◽  
Vol 16 (3) ◽  
pp. 467 ◽  
Author(s):  
Qing Xu ◽  
Yi-Jing Chen ◽  
Zhu-Qing Liu ◽  
Li Chu ◽  
Jue-Min Fang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein

scholarly journals Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Liang Zhou ◽  
Xiang Cai ◽  
Qiang Liu ◽  
Zhong-Yu Jian ◽  
Hong Li ◽  
...  
Keyword(s):  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein ◽  
Urological Cancers

scholarly journals Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis

2013 ◽  
Vol 14 (10) ◽  
pp. 5735-5740 ◽  
Author(s):  
Qing Yu ◽  
Xiong-Fei Yu ◽  
Shou-De Zhang ◽  
Hao-Hao Wang ◽  
Hai-Yong Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein

scholarly journals C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis

2017 ◽  
Vol 26 (143) ◽  
pp. 160070 ◽  
Author(s):  
Giovanni Leuzzi ◽  
Carlotta Galeone ◽  
Francesca Taverna ◽  
Paola Suatoni ◽  
Daniele Morelli ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Chronic Obstructive ◽  
C Reactive Protein ◽  
Obstructive Pulmonary Disease ◽  
Late Mortality ◽  
Reactive Protein ◽  
Copd Patients ◽  
Asiatic Population

The prognostic role of baseline C-reactive protein (CRP) in chronic obstructive pulmonary disease (COPD) is controversial. In order to clarify this issue, we performed a systematic review and meta-analysis to assess the predictive effect of baseline CRP level in COPD patients. 15 eligible articles focusing on late mortality in COPD were included in our study. We performed a random-effects meta-analysis, and assessed heterogeneity and publication bias. We pooled hazard ratio (HR) estimates and their 95% confidence intervals on mortality for the comparison between the study-specific highest category of CRP levelversusthe lowest category. In overall analysis, elevated baseline CRP levels were significantly associated with higher mortality (HR 1.53, 95% CI 1.32–1.77,I2=68.7%, p<0.001). Similar results were observed across subgroups. However, higher mortality risk was reported in studies using a cut-off value of 3 mg·L−1(HR 1.61, 95% CI 1.12–2.30) and in those enrolling an Asiatic population (HR 3.51, 95% CI 1.69–7.31). Our analysis indicates that baseline high CRP level is significantly associated with higher late mortality in patients with COPD. Further prospective controlled studies are needed to confirm these data.

scholarly journals Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A.

Gut ◽  
1992 ◽  
Vol 33 (9) ◽  
pp. 1264-1267 ◽  
Author(s):  
J A Viedma ◽  
M Perez-Mateo ◽  
J E Dominguez ◽  
F Carballo
Keyword(s):  
Acute Pancreatitis ◽  
Interleukin 6 ◽  
Phospholipase A ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-14 ◽  
Author(s):  
Erhu Fang ◽  
Xiaolin Wang ◽  
Jiexiong Feng ◽  
Xiang Zhao
Keyword(s):  
Fixed Effects ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Fixed Effects Model ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein

Backgrounds. Both pretreatment serum CRP (C-reactive protein) level and ALB (albumin) level have been found to be predictive of survival for multiple malignancies including sarcoma. Since both of the GPS (Glasgow prognostic score) and CAR (C-reactive protein to albumin ratio) are based on the combination of CRP and ALB, we conducted a meta-analysis to evaluate the prognostic role of these two parameters for sarcoma patients. Methods. A detailed literature search was conducted in MEDLINE, Embase, and Cochrane Library for relevant research publications written in English. Patients’ clinical characteristics, outcomes of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were extracted. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were combined to evaluate the prognostic role of GPS or CAR. Results. Twelve articles containing 2695 patients were identified as eligible studies. The results showed that an elevated GPS was significantly correlated with poor OS (HR=2.42; 95% CI: 1.98-2.94; p<0.001; fixed-effects model), DSS (HR=2.28; 95% CI: 1.75-2.97; p<0.001; fixed-effects model), and DFS (HR=2.05; 95% CI: 1.62-2.60; p<0.001; fixed-effects model). A higher CAR also was shown to be significantly correlated with poor OS (HR=2.23; 95% CI: 1.70-2.92; p<0.001; fixed-effects model) and DFS (HR=1.81; 95% CI: 1.7-2.58; p=0.001; fixed-effects model). Conclusion. An elevated GPS is predictive of poor survival in patients with sarcomas and is promising to be used as a factor for risk stratification. A higher CAR value is also predictive of poor survival; however, the optimal CAR cut-off value is still to be determined.

Sign in / Sign up

Export Citation Format

Share Document